Osteoprotegerin binding proteins

Details Osteoprotegerin binding proteins Osteoprotegerin binding proteins

2006-08-29

2006-08-29

Kemmerer, Elizabeth (Department: 1646)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S133100, C424S134100, C424S136100, C424S139100, C424S141100, C424S142100

Reexamination Certificate

active

07097834

ABSTRACT:
A novel polypeptide, osteoprotegerin binding protein, involved in osteolcast maturation has been identified based upon its affinity for osteoprotegerin. Nucleic acid sequences encoding the polypeptide, or a fragment, analog or derivative thereof, vectors and host cells for production, methods of preparing osteoprotegerin binding protein, and binding assays are also described. Compositions and methods for the treatment of bone diseases such as osteoporosis, bone loss due to arthritis or metastasis, hypercalcemia, and Paget's disease are also provided.

REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 5763223 (1998-06-01), Wiley et al.
patent: 5843678 (1998-12-01), Boyle
patent: 5961974 (1999-10-01), Armitage et al.
patent: 6017729 (2000-01-01), Anderson et al.
patent: 6150090 (2000-11-01), Baltimore et al.
patent: 6242213 (2001-06-01), Anderson
patent: 6410516 (2002-06-01), Baltimore et al.
patent: 6419929 (2002-07-01), Anderson
patent: 6525180 (2003-02-01), Gorman et al.
patent: 6645500 (2003-11-01), Halkier et al.
patent: 6740522 (2004-05-01), Anderson
patent: 2003/0103978 (2003-06-01), Deshpande et al.
patent: 2003/0104485 (2003-06-01), Boyle
patent: 2003/0176647 (2003-09-01), Yamaguchi et al.
patent: 2003/0208045 (2003-11-01), Yamaguchi et al.
patent: 2005/0003457 (2005-01-01), Yamaguchi et al.
patent: 0816380 (1998-01-01), None
patent: 0873998 (1998-10-01), None
patent: 0 911 342 (1999-04-01), None
patent: 11009269 (1999-01-01), None
patent: WO 86/00922 (1986-02-01), None
patent: WO 90/14363 (1990-11-01), None
patent: WO93/12227 (1993-06-01), None
patent: WO96/26271 (1996-08-01), None
patent: WO 96/34095 (1996-10-01), None
patent: WO 97/23614 (1997-07-01), None
patent: WO 98/25958 (1998-06-01), None
patent: WO 98 25958 (1998-06-01), None
patent: WO 98/28423 (1998-07-01), None
patent: WO 98 28426 (1998-07-01), None
patent: WO 98/54201 (1998-12-01), None
patent: WO 99/29865 (1999-06-01), None
patent: WO 99/65449 (1999-12-01), None
patent: WO 99/65495 (1999-12-01), None
patent: WO 01/23549 (2001-04-01), None
patent: WO 02/15846 (2002-02-01), None
Suda T et al, Modulation of Osteoclast Differentiatio by Local Factors, Bone, vol. 17, 87S-91S, Aug. 1, 1995.
Cooke et al, An overview of progress in antisense therapeutics, Antisense & Nucleic Acid Drug Development, 8:115-122, Jan. 1, 1998.
Takahashi, Biochem. Biophys. Res. Comm. 256, 449-455, 1999.
Goh et al., Protein Engineering 4, 785-791 (1991).
Banner et al., Cell 73, 431-445 (1993).
Chomczynski and Sacchi. Anal. Biochem. 162, 156-159, (1987).
Goeddel, D.V. ed., Methods in Enzymology v. 185, Academic Press (1990).
Gribskov et al. Proc. Natl. Acad. Sci. USA 83, 4355-4359 (1987).
Jimi et al., Endocrinology 137, 2187-2190 (1996).
Lüethy et al. Protein Sci. 3, 139-146 (1994).
Nagata and Golstein, Science 267, 1449-1456 (1995).
Pearson, Meth. Enzymol. 183, 63-98 (1990).
Remington's Pharmaceutical Sciences, 18th ed. A.R. Gennaro, ed. Mack, Easton, PA (1980).
Sambrook et al.Molecular Cloning: A Laboratory ManualCold Spring Harbor Press, New York (1989).
Jones et al., J. Cell. Sci. Suppl. 13, 11-18 (1990).
Smith et al., Cell 76, 959-962 (1994).
Wiley et al. Immunity 3, 673-382 (1995).
Yasuda et al., Proceeds of the National Academy of Sciences of USA 95, 3597-3602 (1998).
E.M.B.L. Databases Accession No. AA170348 (1997).
* Lacey et al., Cell 93: 165-176 (1998).
* Wong, et al, J. Biol. Chem. 272: 25190-25194 (1997).
* Anderson et al., Nature 390: 175-179 (1997).
Tsukii et al, “Osteoclast Differentiation Factor Mediates an Essential Signal for Bone Resorption . . . ”, Biochemical and Biophysical Research Communications, 246, pp 337-341 (1998).
U.S. Appl. No. 09/957,944, filed Sep. 20, 2001, Dougall.
U.S. Appl. No. 10/151,071, filed May 17, 2002, Dougall et al.
U.S. Appl. No. 10/166,232, filed Jun. 5, 2002, Dougall.
U.S. Appl. No. 10/405,878, filed Apr. 1, 2003, Anderson.
Boylev.Gorman and Mattson, Board of Patent Appeals and Interferences, Interference No. 104,336, Paper No. 39.
Camerini et al.,J. Immunol., “The T Cell Activation Antigen CD27 is a Member of the Nerve Growth Factor/Tumor Necrosis Factor Receptor Gene Family”, 147:3165-3169 (1991).
Caux et al.,J. Exp. Med., “Activation of Human Dendritic Cells through CD40 Cross-linking”, 180:1263-1272 (1994).
Dürkop et al.,Cell, “Molecular Cloning and Expression of a New Member of the Nerve Growth Factor Receptor Family That Is Characteristic for Hodgkin's Disease”, 68:421-427 (1992).
EMBL-EBI Database Entry HS421358, Accession No. W74421,Homo sapienscDNA Clone IMAGE:346544 3′ Similar to Contains Alu Repetitive Element, Hillier et al., (Jun. 1996).
Galibert et al.,J. Biol. Chem., “The Involvement of Multiple Tumor Necrosis Factor Receptor (TNFR)-Associated Factors in the Signaling Mechanisms of Receptor Activator of NF-κB, a Member of the TNFR Superfamily”, 273(51):34120-34127 (1998).
Gray et al.,Genetics, “P-Element-Induced Recombination inDrosophila melanogaster. Hybrid Element Insertion”, 144(4):1601-1610 (1996).
Itoh et al.,Cell, “The Polypeptide Encoded by the cDNA for Human Cell Surface Antigen Fas Can Mediate Apoptosis”, 66:233-243 (1991).
Johnson et al.,Cell, “Expression and Structure of the Human NGF Receptor”, 47:545-554 (1986).
Kodaira et al.,Gene, “Cloning and characterization of the gene encoding mouse osteoclast differentiation factor”, 230:121-127 (1999).
Kwon et al.,Proc. Natl. Acad. Sci. USA, “cDNA sequences of two inducible T-cell genes”, 86:1963-1967 (1989).
Mallett et al.,EMBO J., “Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes—a molecule related to nerve growth factor receptor”, 9:1063-1068 (1990).
NCBI, Marra et al., The WashU-HHMI Mouse EST Project, GenBank Accession No. AA170348, (Feb. 16, 1997).
Nakagawa et al.,Biochem. Biophys. Res. Commun., “RANK is the Essential Signaling Receptor for Osteoclast Differentiation Factor in Osteoclastogenesis”, 253:395-400 (1998).
Romani et al.,J. Exp. Med., “Proliferating Dendritic Cell Progenitors in Human Blood”, 180:83-93 (1994).
Rothe, M. et al.,Cell, “The TNFR2-TRAF Signaling Complex Contains Two Novel Proteins Related to Baculoviral Inhibitor of Apoptosis Proteins”, 83:1243-1252 (1995).
Schall, et al.,Cell, “Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor”, 61:361-370 (1990).
Simonet et al.,Cell, “Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density”, 89:309-319 (1997).
Stamenkovic et al.,EMBO J., “A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas”, 8:1403-1410 (1989).
Suda et al.,Endocr. Rev., “Modulation of Osteoclast Differentiation”, 13:66-80 (1992).
Suda et al.,Bone, “Modulation of Osteoclast Differentiation by Local Factors”, 17(2):87S-91S (1995).
Suda et al.,Endocr. Rev., Monograph, “Modulation of Osteoclast Differentiation: Update 1995”, 4(1):266-270 (1995).
Viney et al.,J. Immunol., “Expanding Dendritic Cells In Vivo Enhances the Induction of Oral Tolerance”, 160:5815-5825 (1998).
Wong et al.,J. Biol. Chem. “The TRAF Family of Signal Transducers Mediates NF-κB Activation by the TRANCE Receptor”, 273(43):28355-28359 (1998).
Wong et al.,J. Exp. Med., “TRANCE (Tumor Necrosis Factor [TNF]-related Activation-induced Cytokine), a New TNF Family Member Predominantly Expressed in T cells, Is a Dendritic Cell-specific Survival Factor”, 186:2075-2080 (1997).
Xu et al.,Immunity, “Targeted Disruption of TRAF3 Leads to Postnatal Lethality and Defective T-Dependent Immune Responses”, 5:407-415 (1996).
Yun et al.,Immunol., “OPG/FDCR-1, a TNF Receptor Family Member, Is Expressed in Lymphoid Cells and Is Up-Regulated by Ligating CD401”, 161:6113-6121 (1998).
Jakovits, Aya,

Affiliated with

Also associated with

Rating

Osteoprotegerin binding proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Osteoprotegerin binding proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Osteoprotegerin binding proteins will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3627481